HUMABFC
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

HUMABFC Trademark

Serial Number: 79207192 • Registration: 5510331

HUMABFC is a trademark filed by LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES on December 14, 2016. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Trademark Details

Filing Date

December 14, 2016

Registration Date

July 10, 2018

Published for Opposition

April 24, 2018

Cancellation Date

January 24, 2025

Goods & Services

Scientific and technological services, namely, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; testing, inspection or research of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; scientific research services using protein expression platform technology for research and development of pharmaceuticals; scientific research services using protein expression platform technology for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; scientific laboratory services in the field of monoclonal antibodies

Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
May 14, 2026 INNT
GENERIC MADRID TRANSACTION SENT TO IB
Apr 21, 2026 XXSS
GENERIC MADRID TRANSACTION CREATED
Apr 21, 2026 XXCR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 24, 2025 INTR
CANCELLED SECTION 71
Jan 24, 2025 C71T
NEW REPRESENTATIVE AT IB RECEIVED
May 4, 2024 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jul 10, 2023 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Apr 9, 2021 NREP
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Apr 6, 2021 CORN
CORRECTION TRANSACTION RECEIVED FROM IB
Apr 3, 2021 CRCV
NEW REPRESENTATIVE AT IB RECEIVED
Mar 5, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 21, 2018 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Oct 16, 2018 XXSS
GENERIC MADRID TRANSACTION CREATED
Oct 16, 2018 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 10, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 10, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 24, 2018 NPUB
PUBLISHED FOR OPPOSITION
Apr 24, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Apr 20, 2018 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 4, 2018 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 4, 2018 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 4, 2018 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 17, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 6, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 5, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 5, 2018 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 11, 2017 GNFN
FINAL REFUSAL E-MAILED
Dec 11, 2017 GNFR
FINAL REFUSAL WRITTEN
Dec 11, 2017 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 14, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 14, 2017 CRFA
ASSIGNED TO LIE
Nov 3, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 24, 2017 TROA
REFUSAL PROCESSED BY IB
Jun 10, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 23, 2017 RFCS
REFUSAL PROCESSED BY MPU
May 23, 2017 RFRR
APPLICATION FILING RECEIPT MAILED
May 17, 2017 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 14, 2017 RFCR
NON-FINAL ACTION WRITTEN
May 13, 2017 CNRT
ASSIGNED TO EXAMINER
May 13, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 13, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 11, 2017 REPR